{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:02:08Z","timestamp":1785859328091,"version":"3.56.0"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The present study aimed to better define the usefulness of <jats:sup>18<\/jats:sup>F-FDG PET\/CT in predicting pathological tumor response (PTR) and survival in patients with noncardia gastric cancer treated with preoperative chemotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Seventy-one patients were recruited in 6 Italian centers. The SUV of <jats:sup>18<\/jats:sup>F-FDG PET\/CT was measured at baseline and after treatment, and the difference (dSUV) was computed. The association between PET indexes and PTR, assessed by the Becker score, was evaluated by nonparametric regression. The discriminant power of PET indexes with respect to the absence of PTR (Becker 2\/3) was studied by receiver operating characteristic (ROC) curve and synthesized by the area under the curve (ROC-AUC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>dSUV allowed to partially discriminate between absence\/presence of PTR, when expressed as either absolute value (ROC-AUC, 0.73; 95% confidence interval, 0.59\u20130.87) or percentage (ROC-AUC, 0.74; 95% confidence interval, 0.59\u20130.89). However, only extreme values of percent dSUV were really informative. All 7 patients whose <jats:sup>18<\/jats:sup>F-FDG uptake had increased despite preoperative treatment showed no tumor regression at pathologic examination. Seven of the 10 patients whose metabolic response had been 70% or greater had complete or nearly complete pathologic tumor regression (Becker score 1a or 1b). The metabolic response of the remaining 54 patients, which ranged between 0% and 70%, did not permit to reliably forecast pathologic tumor regression. Survival significantly decreased with increasing Becker score but was unaffected by metabolic response.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The present study suggests that <jats:sup>18<\/jats:sup>F-FDG PET\/CT has limited usefulness in predicting cancer regression. The lack of metabolic response in serial measurements indicates the probable ineffectiveness of preoperative treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000002911","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T16:43:41Z","timestamp":1579884221000},"page":"177-181","source":"Crossref","is-referenced-by-count":4,"title":["Limited Usefulness of 18F-FDG PET\/CT in Predicting Tumor Regression After Preoperative Chemotherapy for Noncardia Gastric Cancer"],"prefix":"10.1097","volume":"45","author":[{"given":"Paolo","family":"Morgagni","sequence":"first","affiliation":[{"name":"Department of Surgery, Morgagni-Pierantoni Hospital, Forl\u00ec"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Bencivenga","sequence":"additional","affiliation":[{"name":"Department of General and Upper GI Surgery, Borgo Trento Hospital, Verona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Colciago","sequence":"additional","affiliation":[{"name":"Department of Surgery, Morgagni-Pierantoni Hospital, Forl\u00ec"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Tringali","sequence":"additional","affiliation":[{"name":"Department of General and Upper GI Surgery, Borgo Trento Hospital, Verona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Giacopuzzi","sequence":"additional","affiliation":[{"name":"Department of General and Upper GI Surgery, Borgo Trento Hospital, Verona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Framarini","sequence":"additional","affiliation":[{"name":"Department of Surgery, Morgagni-Pierantoni Hospital, Forl\u00ec"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Saragoni","sequence":"additional","affiliation":[{"name":"Pathology Unit, Morgagni-Pierantoni Hospital, Forl\u00ec"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Mura","sequence":"additional","affiliation":[{"name":"Surgical Unit, Santa Maria alla Gruccia, Montevarchi General Hospital, Arezzo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigina","family":"Graziosi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Santa Maria della Misericordia, Perugia University, Perugia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Marino","sequence":"additional","affiliation":[{"name":"Department of Surgery, Santa Maria della Misericordia, Perugia University, Perugia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uberto","family":"Fumagalli Romario","sequence":"additional","affiliation":[{"name":"Humanitas Clinical Institute IRCCS, Milan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Baiocchi","sequence":"additional","affiliation":[{"name":"Surgical Clinic, Department of Clinical and Experimental Sciences, University Hospital Brescia, Brescia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Moretti","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, Morgagni-Pierantoni Hospital, Forl\u00ec"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vania","family":"Rossi","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, San Donato Hospital, Arezzo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Verlato","sequence":"additional","affiliation":[{"name":"Unit of Epidemiology and Medical Statistics, University of Verona, Verona, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,1,30]]},"reference":[{"key":"bib1-20230925","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","year":"2006","journal-title":"N Engl J Med"},{"key":"bib2-20230925","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial","volume":"29","year":"2011","journal-title":"J Clin Oncol"},{"issue":"suppl 6","key":"bib3-20230925","first-page":"vi57","article-title":"ESMO Guidelines Committee. Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","year":"2013","journal-title":"Ann Oncol"},{"key":"bib4-20230925","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s10120-016-0615-3","article-title":"The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015","volume":"20","year":"2017","journal-title":"Gastric Cancer"},{"key":"bib5-20230925","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1200\/JCO.2003.06.574","article-title":"Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial","volume":"21","year":"2003","journal-title":"J Clin Oncol"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/1078-0432.CCR-07-0934","article-title":"Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study","volume":"14","year":"2008","journal-title":"Clin Cancer Res"},{"key":"bib7-20230925","doi-asserted-by":"crossref","first-page":"506","DOI":"10.21037\/jgo.2016.06.01","article-title":"Use of positron emission tomography scan response to guide treatment change for locally advanced gastric cancer: the memorial Sloan Kettering Cancer Center experience","volume":"7","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"bib8-20230925","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1245\/s10434-011-1743-y","article-title":"Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer","volume":"18","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"bib9-20230925","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jso.21592","article-title":"[18F]-fluorodeoxyglucose\u2013positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer","volume":"102","year":"2010","journal-title":"J Surg Oncol"},{"key":"bib11-20230925","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/apm.1965.64.1.31","article-title":"The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification","volume":"64","year":"1965","journal-title":"Acta Pathol Microbiol Scand"},{"key":"bib12-20230925","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/cncr.11660","article-title":"Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy","volume":"98","year":"2003","journal-title":"Cancer"},{"key":"bib13-20230925","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10120-015-0575-z","article-title":"Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification","volume":"19","year":"2016","journal-title":"Gastric Cancer"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T06:10:38Z","timestamp":1695622238000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002911"}},"subtitle":["The Italian Research Group for Gastric Cancer (GIRCG) Experience"],"short-title":[],"issued":{"date-parts":[[2019,1,30]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000002911","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1,30]]}}}